In an experimental setting, antagonizing TGF-β resulted in increased infarct volume [178], while intranasal administration of TGF-β reduced infarct volume and enhanced neurogenesis after ischemic stroke in mice [179]. The gene discussed is TGFB1; the disease is ischemic stroke.